Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coya Therapeutics, Inc. - Common Stock (NQ: COYA ) 7.260 +0.520 (+7.72%) Official Closing Price Updated: 4:15 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 58,301 Open 7.080 Bid (Size) 6.650 (1) Ask (Size) 7.310 (12) Prev. Close 6.740 Today's Range 6.600 - 7.400 52wk Range 4.400 - 10.69 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results Today 8:00 EST From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer November 01, 2024 From Coya Therapeutics, Inc. Via Business Wire Performance YTD +4.31% +4.31% 1 Month +1.68% +1.68% 3 Month +21.81% +21.81% 6 Month -9.59% -9.59% 1 Year +42.49% +42.49% More News Read More Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study October 29, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session October 29, 2024 Via Benzinga Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain) October 29, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease October 28, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Closing of $10.0 Million Private Placement October 23, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces $10.0 Million Private Placement October 22, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 October 08, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference September 24, 2024 From Coya Therapeutics, Inc. Via Business Wire This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday September 16, 2024 Via Benzinga Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease September 16, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Present at Upcoming Healthcare Conferences September 03, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 August 19, 2024 From Coya Therapeutics, Inc. Via Business Wire COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 August 12, 2024 Via InvestorPlace Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results August 12, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid August 02, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists July 31, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic June 20, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology June 11, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology June 03, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index May 28, 2024 From Coya Therapeutics, Inc. Via Business Wire 7 Biotech Stocks to Put on Your Breakthrough Radar May 27, 2024 Via InvestorPlace EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases May 27, 2024 Via Benzinga Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease May 22, 2024 From Coya Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
